Don't miss our holiday offer - up to 50% OFF!
CJC-1295 (with DAC)
Price range: $66.50 through $630.00
Batch Number: 145030
Purity Percentage: 99.63
Identity Confirmation: CJC-1295 DAC ID Confirmed
Testing Methods: HPLC-UV/MS
Credential Line: 200513
Test Date: 09/02/2026
Research Data
Research Classification
Long-Acting GHRH Analog / Growth Hormone-Releasing Hormone Research Peptide
Molecular Structure
Structure Description
CJC-1295 with DAC is a modified GHRH(1-29)-derived peptide incorporating amino-acid substitutions that increase enzymatic stability and a Drug Affinity Complex containing a reactive maleimide group. The DAC moiety is designed to form a covalent bond with circulating albumin, substantially extending peptide persistence compared with non-DAC GHRH analogs.
Research Discipline
Endocrinology; Peptide Biology; GHRH/GH/IGF-1 Axis Research; Pharmacology; Peptide Bioconjugation; Pituitary Biology
Molecular Formula
C₁₆₅H₂₆₉N₄₇O₄₆ PubChem reports this molecular formula for CJC-1295 with the DAC modification.
Molecular Weight
3647.2 g/mol PubChem reports a molecular weight of 3647.2 g/mol for CJC-1295.
CAS Number
446036-97-1 — COA-reported This is the CAS number reported by Krause Analytical for the actual CJC-1295 DAC sample tested.
Amino Acid Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(DAC)-NH₂
Common shorthand:
H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-(Nε-maleimidopropionyl)Lys-NH₂
This sequence represents the DAC-modified CJC-1295 structure described in structural references for the molecule.
Primary Molecular Target
Growth Hormone-Releasing Hormone Receptor (GHRHR) Secondary structural interaction: Serum albumin via the DAC maleimide functionality Published research describes CJC-1295 as a GHRH analog that activates the GHRH receptor while its DAC moiety enables covalent albumin association.
Experimental Applications
GHRH receptor signaling studies
Growth hormone secretion research
IGF-1 signaling studies
Pituitary-cell research
Albumin-binding peptide research
Long-acting peptide pharmacology
Peptide bioconjugation research
GH pulsatility analysis
Endocrine signaling studies
Pharmacokinetic and pharmacodynamic research
Experimental Systems
Published research systems involving CJC-1295 include:
GHRH receptor activation models
Rat anterior pituitary systems
GHRH-knockout mouse models
Healthy adult human research subjects
Serum GH and IGF-1 measurement systems
Pharmacokinetic models
Albumin-binding biochemical systems
Pituitary gene-expression models
CJC-1295 has been evaluated in animal and controlled human research, including studies of GH and IGF-1 responses.
Specific Assays
HPLC-UV chromatographic purity analysis
LC-MS identity confirmation
Mass-spectrum/reference-spectrum matching
GHRH receptor activation assays
Serum GH assays
Serum IGF-1 assays
Pharmacokinetic analysis
Albumin-binding studies
GH pulsatility analysis
Pituitary GH mRNA analysis
Immunohistochemistry
Endocrine biomarker analysis
The actual OPTMZ product was characterized using HPLC-UV-MS with mass-spectrum/reference-spectrum comparison.
Measured Endpoints
Chromatographic purity
Peptide identity
Peptide content
GHRHR activation
Circulating GH concentration
Circulating IGF-1 concentration
GH pulsatility
Albumin association
Pharmacokinetic persistence
Pituitary GH gene expression
Somatotroph-associated responses
For the actual OPTMZ lot, the directly measured analytical endpoints were chromatographic purity, identity, and net CJC-1295 DAC content.
Extra Features
- Premium Quality
- Secure Payments
- Satisfaction Guarantee
- Worldwide Shipping
- Money Back Guarantee
Technical Specifications
- Product: CJC-1295 (with DAC)
- Quantity: 2 mg label claim
- Research Classification: Long-Acting GHRH Analog
- Compound Type: Modified Peptide Hormone Analog
- Primary Research Target: Growth Hormone-Releasing Hormone Receptor (GHRHR)
- COA-Reported CAS Number: 446036-97-1
- Chromatographic Purity: 99.63%
- Identity: CJC-1295 DAC confirmed by HPLC-UV-MS
- Measured Content: 2.44 mg
- Percent of Label: 122.0%
- Analysis Method: HPLC-UV-MS
- Laboratory: Krause Analytical
- Lab Number: 200513
- Project: 145030
- Report Issued: February 9, 2026
The purity, identity, measured content, and CAS number above come directly from the Krause Analytical report for the submitted OPTMZ sample.
For the fully DAC-modified CJC-1295 molecule, PubChem reports molecular formula C₁₆₅H₂₆₉N₄₇O₄₆ and molecular weight 3647.2 g/mol.
Analytical & Testing
Each tested batch of CJC-1295 (with DAC) undergoes analytical evaluation to verify chromatographic purity, identity, peptide content, and analytical consistency.
For the submitted OPTMZ Peptides sample, independent testing by Krause Analytical reported:
- Chromatographic Purity: 99.63%
- Identity: CJC-1295 DAC — Confirmed
- Measured Content: 2.44 mg
- Label Claim: 2 mg
- Percent of Label: 122.0%
- Testing Method: HPLC-UV-MS
- CAS Number: 446036-97-1
The laboratory states that the data presented are from the analyzed sample and meet internal quality-assurance criteria unless otherwise flagged.
The second page of the COA includes the chromatogram and a direct comparison between the sample mass spectrum and the CJC-1295 DAC reference spectrum.
Note: This COA does not report endotoxin testing, so I would not state that this specific lot was endotoxin tested.
Handling & Storage
CJC-1295 (with DAC) should be handled by qualified professionals in controlled laboratory environments. Appropriate storage conditions should be maintained to preserve peptide stability and structural integrity.
Avoid unnecessary exposure to heat, moisture, light, and repeated temperature fluctuations. Experimental preparation, storage, and handling should follow validated laboratory procedures appropriate to the intended research application.
Research Context
CJC-1295 (with DAC) has been investigated in experimental and clinical research involving the GHRH/GH/IGF-1 signaling axis and long-acting peptide pharmacology.
Research areas include:
- GHRH receptor signaling
- Growth hormone secretion
- IGF-1-associated signaling
- Pituitary physiology
- Albumin-binding peptide pharmacology
- Long-acting peptide design
- Endocrine signaling
- Pharmacokinetic research
- Growth hormone pulsatility
- Peptide bioconjugation
CJC-1295 was developed as a modified hGRF(1-29) analog capable of covalent albumin association, thereby extending its plasma persistence. Experimental work identified it as a stable and active hGRF analog with an extended half-life.
Human research has also examined its pharmacokinetics and effects on circulating GH and IGF-1 in controlled studies.
These research findings do not establish that the product supplied here is approved for therapeutic use.
Research Application Scope
CJC-1295 (with DAC) continues to be evaluated as an experimental tool for studying GHRH receptor signaling, pituitary endocrine biology, GH/IGF-1 pathway regulation, albumin-binding peptide design, and extended-duration peptide pharmacology.
The DAC modification is particularly relevant to laboratory investigations of peptide bioconjugation because CJC-1295 is designed to associate with endogenous albumin, extending biological persistence compared with unmodified GHRH analogs.
Use Statement
For laboratory research use only. Intended strictly for in vitro and controlled experimental research applications.
Disclaimer
All products currently listed on this site are for research purposes ONLY.
| Pcs | Single Vial, Pack Of 10 |
|---|---|
| Strength | 5mg |
Be the first to review “CJC-1295 (with DAC)”
Reviews
There are no reviews yet.